Skip to content

Maximizing the Efficacy of Cognitive Behavior Therapy and Contingency Management

Maximizing the Efficacy of Cognitive Behavior Therapy and Contingency Management

Status
Completed
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00350649
Enrollment
205
Registered
2006-07-11
Start date
2004-12-31
Completion date
2010-09-30
Last updated
2011-09-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Marijuana Dependence

Keywords

behavior modification, cognitive behavioral therapy, combination therapy, drug abuse therapy, drug addition, human therapy evaluation, psychotherapy, clinical trial phase II, coping, drug and alcohol abstinence, longitudinal human study, outcomes research, outpatient care, psychological reinforcement, therapy compliance, behavior and social research tag, human subjects, neuropsychological test, patient oriented research

Brief summary

Cognitive-behavioral coping skills therapy (CBT) is a widely used and recognized treatment that has been empirically validated for a range of substance use disorders, often with emergent effects and continuing improvement even after treatment ends. Treatment retention and compliance are associated with enhanced treatment outcomes in CBT. Contingency management (CM) also has very strong support and is associated with rapid, robust effects on targeted outcomes. Despite their many strengths, neither CBT nor CM is universally effective. It is now essential to seek strategies to maximize and extend the effectiveness of these two approaches and to better understand how these treatments exert their effects.

Detailed description

The investigators propose to evaluate targeted strategies to maximize the effectiveness of CBT and CM, respectively. To maximize the effectiveness of CBT, the investigators will evaluate the benefit of adding CM, with reinforcement for session attendance and homework completion, to standard individual CBT for outpatient marijuana abusers, in order to expose participants to more skill training and opportunities for practice of skills. To maximize the effectiveness and durability of CM, we will evaluate the benefit of integrating it with skills training, specifically designed to reduce drop off effects, in order to extend CM's benefits beyond the active treatment period. We propose to conduct a Stage II trial which will: (1) Evaluate the efficacy of four conditions for 160 marijuana dependent outpatients: (a) Standard CBT, (b) CBT with CM reinforcement for attendance and completing homework (CBT+CM/adherence), (c) CM for abstinence alone (CM/abstinence), (d) CM for abstinence integrated with CBT (CM/abstinence+CBT), and (2) Evaluate the longer-term durability and / or delayed emergence of treatment effects after termination of the study treatments through a one-year follow-up. Secondary aims will be to conduct (a) detailed process studies to evaluate whether the proposed enhancements affect proximal and distal outcomes as hypothesized and (b) economic analyses. Study treatments will last 12 weeks.

Interventions

BEHAVIORALStandard CBT

Manualized delivery of CBT by trained clinicians

BEHAVIORALCBT+CM/adherence

CBT and Clinical Management for attendance and completing homework

BEHAVIORALCM/abstinence

Contingency Management

BEHAVIORALCM/abstinence+CBT

Contingency Management for abstinence in addition to manualized CBT delivered by a trained clinician

Sponsors

National Institute on Drug Abuse (NIDA)
CollaboratorNIH
Yale University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* 18-65 year old marijuana dependent * willing to sign consent * no use of prescribed psychotropic drugs * willing to give three individuals as contacts * willing to accept randomization * read and write English (third grade level)

Exclusion criteria

* unable to commit to 1 year follow up

Design outcomes

Primary

MeasureTime frame
Self reported marijuana use (days of abstinence by week) and results of urine toxicology screens12 weeks

Secondary

MeasureTime frame
Economic analysis with use of PACC-SAT12 weeks

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 11, 2026